This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2015
  • /
  • 08
  • /
  • MAA for Ibrance (palbociclib) + endocrine therapy ...
Drug news

MAA for Ibrance (palbociclib) + endocrine therapy accepted by EMA for treatment of HR+/HER2- Metastatic Breast Cancer- Pfizer

Read time: 1 mins
Last updated:27th Aug 2015
Published:27th Aug 2015
Source: Pharmawand

Pfizer announced that the European Medicines Agency has validated its Marketing Authorization Application for Ibrance (palbociclib) in combination with endocrine therapy for the treatment of HR+/HER2- metastatic breast cancer.

The submission is based on the final results of the PALOMA-1 and PALOMA-3 trials in metastatic breast cancer. Both trials demonstrated that palbociclib in combination with an endocrine therapy improved progression-free survival (PFS) compared to endocrine therapy alone.

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news
Dalzanemdor (SAGE 718) did not demonstrate a statistically significant difference from baseline on the primary endpoint in the phase II LIGHTWAVE study for the treatment of mild cognitive impairment and mild dementia in alzheimer’s disease

Sage Therapeutics, Inc. announces topline results from LIGHTWAVE, a 12-week, Phase II randomized, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor (SAGE 718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s Disease (AD)

1 mins
Drug news
Supplemental sNDA to the FDA for vutrisiran for the treatment of transthyretin amyloidosis with cardiomyopathy

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced the submission of its supplemental New Drug Application (sNDA) to the FDA for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM)

1 min
Drug news
Complete Response from FDA for dasiglucagon to prevent and treat congenital hypoglycemia

Zealand Pharma A/S announced that the FDA has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism (CHI) for up to 3 weeks of dosing

1 min
See all news